Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads.
apolipoprotein B-depleted serum
cardiovascular disease
cholesterol efflux capacity
high-density lipoprotein
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
30 04 2019
30 04 2019
Historique:
received:
31
01
2019
revised:
08
03
2019
accepted:
12
03
2019
pubmed:
15
3
2019
medline:
10
4
2020
entrez:
15
3
2019
Statut:
epublish
Résumé
Cholesterol efflux capacity (CEC) in atherosclerotic lesions is the main anti-atherosclerotic function of high-density lipoprotein (HDL). In recent studies, apolipoprotein (apo) B-depleted serum (BDS) obtained with the polyethylene glycol (PEG) precipitation method is used as a cholesterol acceptor (CA) substitution for HDL isolated by ultracentrifugation. However, the suitability of BDS as a CA is controversial. In the present study, CEC obtained from BDS (BDS-CEC) was evaluated based on a parameter, defined as whole-CEC, which was calculated by multiplying CEC obtained using fixed amounts of HDL by cholesterol concentration to HDL-cholesterol (HDL-C) levels in the serum. Significant correlation (r = 0.633) was observed between both CECs. To eliminate systematic errors from possible contamination with serum proteins and low-density lipoprotein (LDL) or very-LDL (VLDL) in BDS-CEC, the deviation of each CEC-BDS from the regression equation was compared with serum protein, LDL, and triglyceride (TG) levels. No correlation was observed between the deviation and the levels of each of these serum components, indicating that the deviations do not derive from systematic error. Further, to evaluate the effects of serum protein on the results, we measured BDS-CEC of reconstituted serum samples prepared using combinations of five levels of serum proteins with five levels of HDL-C. No significant change in BDS-CEC was observed in any combination. These results indicate that BDS-CEC reflects not only the function of HDL but also its concentration in serum.
Identifiants
pubmed: 30867253
pii: BSR20190213
doi: 10.1042/BSR20190213
pmc: PMC6443949
pii:
doi:
Substances chimiques
Apolipoproteins B
0
Cholesterol, HDL
0
Lipoproteins, LDL
0
Lipoproteins, VLDL
0
Liposomes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Author(s).
Références
Clin Chim Acta. 2014 Feb 15;429:111-22
pubmed: 24333390
J Lipid Res. 2006 Mar;47(3):605-13
pubmed: 16327021
J Biol Chem. 2005 Oct 28;280(43):35890-5
pubmed: 16120612
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
J Lipid Res. 2017 Mar;58(3):600-606
pubmed: 28049656
World J Methodol. 2014 Sep 26;4(3):163-88
pubmed: 25332915
J Clin Invest. 1955 Sep;34(9):1345-53
pubmed: 13252080
Atherosclerosis. 2008 Apr;197(2):732-9
pubmed: 17709109
Atherosclerosis. 2013 Dec;231(2):405-10
pubmed: 24267259
Cell Metab. 2013 Aug 6;18(2):225-38
pubmed: 23931754
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2750-2754
pubmed: 30354236
N Engl J Med. 2007 Sep 27;357(13):1301-10
pubmed: 17898099
J Clin Invest. 1951 Oct;30(10):1071-81
pubmed: 14888685
Circulation. 2017 Jun 20;135(25):2494-2504
pubmed: 28450350
J Lipid Res. 1981 Feb;22(2):339-58
pubmed: 6787159
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Scand J Clin Lab Invest. 1976 May;36(3):265-8
pubmed: 181836
Biosci Rep. 2018 Apr 13;38(2):
pubmed: 29545317
Lancet. 2010 Jul 31;376(9738):333-9
pubmed: 20655105
J Lipid Res. 2008 Nov;49(11):2312-22
pubmed: 18622028
Biol Chem. 2019 Jan 28;400(2):209-218
pubmed: 30210053